Today portfolio company, Envisagenics, announce a multi-year research collaboration agreement with Bristol-Myers Squibb. Together, they will leverage Envisagenics’ SpliceCore, a cloud-based AI Platform that identifies alternative splicing targets for therapeutic development to expand their vast oncology pipeline.